Preclinical studies in AML showed that the genetic ablation or pharmacological inhibition of GLUT1 with BAY-876 led to the suppression of leukaemia progression and improved the survival of AML transplanted mice. Here, SLC2A1 is linked to acute myeloid leukemia.